ArticleBMC medical ethics2026
War, ethics, and market presence: policy shifts of global pharmaceutical companies in Russia following the 2022 invasion of Ukraine.
Article in BMC medical ethics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn response to the 2022 Russian invasion of Ukraine, some scholars have advocated for pharmaceutical companies to voluntarily cease all operations and sales in Russia, including essential medicines. This proposal has been criticized on ethical and practical grounds. This study aims to understand the perspectives of global pharmaceutical companies regarding the provision of medicines following the Russian invasion of Ukraine.
methodsWe analyzed press releases and similar statements from the public websites of 19 global pharmaceutical companies following Russia’s invasion of Ukraine. Companies were selected based on third-party reports of top 20 global pharmaceutical companies by revenue. Data were analyzed using conventional content analysis. Two researchers with ethics expertise independently identified key concepts, assessed ethical justifications (consequentialist, deontological, or values-based), and categorized findings.
resultsAnalysis of the press releases revealed two major themes: “scale-back” of non-essential operations in Russia (58% of companies) and a commitment to continuing to sell “essential products or medicines” (79% of companies). Companies scaling back operations often hinted at ethical justifications, including consequentialist, deontological, and values-based reasoning. The commitment to essential medicines was justified using consequentialist, deontological, and values-based reasoning, although values-based reasons were most common.
conclusionGlobal pharmaceutical companies have responded to the Russian invasion of Ukraine with a nuanced approach, characterized by scaling back non-essential operations while maintaining the supply of essential medicines. This approach reflects a complex interplay of ethical, practical, and geopolitical considerations. The findings highlight a shared understanding of the humanitarian imperative to ensure access to life-saving treatments, but they also raise questions about the variable articulation of ethical justifications and the potential influence of economic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.